SEC Form 4 · accession 0001620368-26-000003
Prelude Therapeutics Inc · PRLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Victor Sandor
Director
Period of report
Jun 9, 2026
Accepted (ET)
Jun 10, 2026 · 4:13 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001678660
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (Right to Buy)F1 | $3.94 | Jun 9, 2026 | A | 38,000 | A | — | Jun 8, 2036 | Common Stock | 38,000 | 38,000 | D |
Explanation of responses
- F1The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.